



US005710181A

# United States Patent [19]

Williamson et al.

[11] Patent Number: 5,710,181

[45] Date of Patent: \*Jan. 20, 1998

[54] INHIBITION OF NITRIC OXIDE FORMATION IN INFLAMMATORY BOWEL DISEASE

[75] Inventors: Joseph R. Williamson; John A. Corbett, both of St. Louis; Michael L. McDaniel, Glendale, all of Mo.; Ronald G. Tilton, Sugarland, Tex.

[73] Assignee: Washington University, St. Louis, Mo.

[\*] Notice: The term of this patent shall not extend beyond the expiration date of Pat. Nos. 3,358,969 and 5,246,970.

[21] Appl. No.: 620,833

[22] Filed: Mar. 25, 1996

## Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 328,925, Oct. 25, 1994, abandoned, which is a continuation-in-part of Ser. No. 110,915, Aug. 24, 1993, Pat. No. 5,358,969, which is a continuation-in-part of Ser. No. 843,387, Feb. 28, 1992, Pat. No. 5,246,971, and a continuation-in-part of Ser. No. 906, 632, Jun. 30, 1992, Pat. No. 5,246,970, which is a continuation-in-part of Ser. No. 807,912, Dec. 16, 1991, abandoned.

[51] Int. Cl.<sup>6</sup> ..... A61K 31/155

[52] U.S. Cl. ..... 514/634

[58] Field of Search ..... 514/634

## References Cited

### U.S. PATENT DOCUMENTS

3,541,218	11/1970	Marshall et al.	.
4,758,583	7/1988	Cerami et al.	..... 514/399
4,870,210	9/1989	Musser	.
5,128,360	7/1992	Cerami et al.	.
5,246,970	9/1993	Williamson et al.	..... 514/632
5,246,971	9/1993	Williamson et al.	..... 514/634
5,273,875	12/1993	Griffith	.
5,317,040	5/1994	Goldman et al.	.
5,358,969	10/1994	Williamson et al.	..... 514/632

### FOREIGN PATENT DOCUMENTS

222313 5/1987 European Pat. Off. .

339496 2/1989 European Pat. Off. .  
316852 5/1989 European Pat. Off. .  
3206034 9/1991 Japan .

## OTHER PUBLICATIONS

Southan et al. (1996), Selective Pharmacological Inhibition of Distinct Nitric Oxide Synthase Isoforms, *Biochemical Pharmacology* 51:383-94.

Corbett et al. (1993), Nitric Oxide Mediates IL-1 $\beta$ -Induced Islet Dysfunction And Destruction: Prevention By Dexamethasone, *Autoimmunity* 15:145-53.

Henrich (1990), Diabetes mellitus—ein Krankheitssyndrom und seine Behandlung, *Pharm. Ztg.* 135:1711-24.

Vlassara (1990), Chronic Diabetic Complications and Tissue Glycosylation Relevant Concern for Diabetes—Prone Black Population, *Diabetes Care* 13:1180-1185.

Bucala et al. (1991), Advanced Glycosylation Products Quench Nitric Oxide and Mediate Defective Endothelium-Dependent Vasodilatation in Experimental Diabetes, *J. Clin. Invest.* 87:432-438.

Brownlee et al. (1986), Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking, *Science* 232:1629-1632.

Corbett et al. (1992), Does Nitric Oxide Mediate Autoimmune Destruction of  $\beta$ -Cells?, *Diabetes* 41:897-903.

Martindale, The Extra Pharmacopoeia, 28th ed., J.E.F. Reynolds, Ed., published by The Pharmaceutical Press (London), pp. 466, 467 and 473-477, 1982.

O'Connor et al., *Biochim. Biophys. Acta.*, 1097(3), pp. 227-231 (Biosis Abs. No. 93030356), 1991.

Radomski et al., *Proc. Natl. Sci. USA*, 87(24), pp. 10043-10047 (Biosis Abs. No. 91047745), 1990.

Primary Examiner—Raymond Henley, III  
Attorney, Agent, or Firm—Howell & Haferkamp, L.C.

## ABSTRACT

A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with inflammatory bowel disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.

9 Claims, 8 Drawing Sheets